Not available
Quote | Puma Biotechnology Inc (NASDAQ:PBYI)
Last: | $2.935 |
---|---|
Change Percent: | -2.81% |
Open: | $3.03 |
Close: | $3.02 |
High: | $3.06 |
Low: | $2.9 |
Volume: | 166,241 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Puma Biotechnology Inc (NASDAQ:PBYI)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...
Message Board Posts | Puma Biotechnology Inc (NASDAQ:PBYI)
Subject | By | Source | When |
---|---|---|---|
Awesome weekly chart | mitcheroo | investorshub | 01/26/2023 1:06:50 AM |
znewcar1: $PBYI 20% v1,3M c4.50 f45,6M H4.60 ML2.08 | znewcar1 | investorshangout | 11/22/2022 4:15:11 AM |
Oh man got caught up on the pump | Roadtojourney | investorshub | 01/12/2022 11:09:49 PM |
Historic short interest: | XenaLives | investorshub | 11/22/2021 2:12:16 PM |
Institutional Shares (Long) 36,969,527 - 90.42% (ex 13D/G) - | XenaLives | investorshub | 11/22/2021 2:10:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000 ® Index at the conclusion of Russell Investments’ annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S....